Dyne Therapeutics (DYN) Shares Outstanding (Weighted Average) (2019 - 2026)

Dyne Therapeutics' Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $165.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 50.15% year-over-year to $165.0 million; the TTM figure through Mar 2026 stood at $165.0 million (up 50.15% YoY), while the FY2025 annual figure was $128.4 million, up 36.43% from the prior year.
• Shares Outstanding (Weighted Average) was $165.0 million for Q1 2026 at Dyne Therapeutics, up from $128.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $165.0 million in Q1 2026 to a low of $51.6 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $85.1 million across 5 years, with a median of $81.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) climbed 0.83% in 2022, then soared 70.67% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $52.0 million in 2022, then gained by 14.83% to $59.7 million in 2023, then soared by 57.74% to $94.1 million in 2024, then soared by 36.43% to $128.4 million in 2025, then gained by 28.49% to $165.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $165.0 million (Q1 2026), $128.4 million (Q4 2025), and $122.0 million (Q3 2025), per Business Quant data.